Key statistics
On Friday, Prelude Therapeutics Inc (PRLD:NSQ) closed at 0.9487, 1.90% above its 52-week low of 0.931, set on Nov 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.96 |
---|---|
High | 0.97 |
Low | 0.939 |
Bid | 0.937 |
Offer | 1.01 |
Previous close | 0.9672 |
Average volume | 346.82k |
---|---|
Shares outstanding | 55.04m |
Free float | 51.21m |
P/E (TTM) | -- |
Market cap | 53.23m USD |
EPS (TTM) | -1.77 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
- Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
- Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
- Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
- Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
- Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
- Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
- Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
More ▼